Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.15403/jgld-4717 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
PPAR agonists for the treatment of cholestatic liver diseases: Over a decade of clinical progress.
Hepatol Commun
January 2025
Department of Biomedical and Pharmaceutical Sciences, College of Pharmacy, University of Rhode Island, Kingston, Rhode Island, USA.
Article Synopsis
- Primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) are liver diseases that damage bile ducts, leading to bile accumulation, liver injury, and increased risk of liver failure; current treatments are limited, especially for PSC.
- Ursodeoxycholic acid is the first-line treatment for PBC, but many patients do not respond fully, indicating a need for better therapies; pruritus (itching) is a common and severe symptom due to cholestasis that is often inadequately treated.
- The review examines the use of PPAR agonists, a type of medication that targets liver metabolism, as potential second-line treatments for PBC and PSC, highlighting recent FDA approvals for
The effect of serum triglyceride levels and different lipid-lowering methods on the prognosis of hypertriglyceridemic acute pancreatitis: a single-center 12-year retrospective study by propensity score matching.
Scand J Gastroenterol
July 2024
Department of Gastroenterology, Civil Aviation General Hospital, School of Civil Aviation Clinical Medicine, Peking University, Beijing, China.
Aim: To investigate the impact of triglyceride on hypertriglyceridemic acute pancreatitis (HTG-AP) and different lipid-lowering methods on triglyceride-lowering efficiency and HTG-AP.
Methods: The patients with HTG-AP from January 2012 to December 2023 in Civil Aviation General Hospital were analyzed, retrospectively. Patients were divided and compared according to whether their triglycerides were below 5.
Treatment in primary biliary cholangitis: Beyond ursodeoxycholic acid.
Eur J Intern Med
June 2024
Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Center Rotterdam, Doctor Molewaterplein 40, NA building, Floor 6, Rotterdam 3015 GD, the Netherlands. Electronic address:
Primary biliary cholangitis (PBC) is a rare cholestatic immune-mediated liver disease. The clinical course varies from mild to severe, with a substantial group of patients developing cirrhosis within a decade. These patients are at risk of hepatocellular carcinoma, decompensation and liver failure.
View Article and Find Full Text PDFBezafibrate severe late onset drug-induced liver injury in primary biliary cholangitis: case report.
J Gastrointestin Liver Dis
September 2023
Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte; Instituto Alfa de Gastroenterologia, Hospital das Clínicas da Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.
Current Clinical Trial Status and Future Prospects of PPAR-Targeted Drugs for Treating Nonalcoholic Fatty Liver Disease.
Biomolecules
August 2023
Department of Health Chemistry, Showa Pharmaceutical University, Machida, Tokyo 194-8543, Japan.
The number of patients with nonalcoholic fatty liver disease (NAFLD)/nonalcoholic steatohepatitis (NASH) is increasing globally and is raising serious concerns regarding the increasing medical and economic burden incurred for their treatment. The progression of NASH to more severe conditions such as cirrhosis and hepatocellular carcinoma requires liver transplantation to avoid death. Therefore, therapeutic intervention is required in the NASH stage, although no therapeutic drugs are currently available for this.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!